Analyst firms · UBS · EW
UBS EW price target and rating history
Edwards Lifesciences Corporation (EW) · Health Care
UBS rates Edwards Lifesciences Corporation (EW) Buy with a $110 price target, as of its latest action on Jul 28, 2026. It has published 5 rating actions on EW since July 2021, including 1 upgrade and 0 downgrades. Across 7 firms with a EW price target in the last 12 months, the median target is $110. UBS's target matches it.
- Current rating
- Buy
- Price target
- $110
- Median target, all firms
- $110
- Actions on EW
- 5
UBS price target on EW
Every UBS rating on EW
- Jul 28, 2026
- Mar 29, 2023
- Feb 2, 2022
- Jan 27, 2022
- Jul 30, 2021
How other firms rate EW
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Robert W. Baird | Outperform | $116 | Nov 5, 2026 |
| Truist Securities | Buy | $113 | Nov 4, 2026 |
| Barclays | Overweight | $110 | Oct 7, 2026 |
| UBS | Buy | $110 | Jul 28, 2026 |
| Leerink Partners | Outperform | $101 | Jul 24, 2026 |
| Wolfe Research | Outperform | $92 | Apr 1, 2026 |
| TD Cowen | Buy | $97 | Jan 9, 2026 |
Questions about UBS and EW
- What is UBS's price target for EW?
- UBS's latest stated price target for Edwards Lifesciences Corporation (EW) is $110, from its action on Jul 28, 2026.
- What is UBS's rating on EW?
- UBS rates EW Buy, a bullish rating, as of Jul 28, 2026.
- When did UBS last change its view on EW?
- On Jul 28, 2026, UBS starts coverage at Buy, price target $110.
- How does UBS's EW target compare with other analysts?
- Across 7 firms with a EW price target in the last 12 months, the median target is $110. UBS's target matches it.
More EW rating histories
- Robert W. Baird3
- Truist Securities3
- Leerink Partners6
- Wolfe Research6
- Raymond James6
- Jefferies4
- Oppenheimer4
- Evercore ISI3
- Piper Sandler4
- Stifel4
- BofA Securities4
- Morgan Stanley6
- Citigroup4
- Wells Fargo6
- Credit Suisse3
All UBS ratingsEW news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.